Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9543966 | 1.00 | OPRD1 (0.47) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL5064869 | 0.88 | OPRD1 (0.49) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL29163531 | 0.88 | OPRD1 (0.49) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL4595926 | 0.88 | OPRD1 (0.49) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL29401750 | 0.88 | OPRD1 (0.49) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL18914431 | 0.87 | OPRD1 (0.48) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL17572840 | 0.86 | OPRD1 (0.48) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL3929271 | 0.84 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL10207323 | 0.84 | OPRD1 (0.50) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL2081318 | 0.84 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| CN-103068830-A | Arginase inhibitors and therapeutic uses thereof | MARS INC | 2013-04-24 | — | — | CN | disclosed |
| EP-2560978-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | OPRD1 939/4885NAMPT 3152/4885MEN1 2806/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | OPRD1 939/4885NAMPT 3152/4885MEN1 2806/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | OPRD1 939/4885NAMPT 3152/4885MEN1 2806/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | OPRD1 939/4885NAMPT 3152/4885MEN1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.